Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
95 hedge funds and large institutions have $853M invested in Avidity Biosciences in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 29 reducing their positions, and 17 closing their positions.
15% more capital invested
Capital invested by funds: $739M → $853M (+$114M)
1.67% more ownership
Funds ownership: 90.15% → 91.82% (+1.7%)
5% less funds holding
Funds holding: 100 → 95 (-5)
14% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 29
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.1M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$7.83M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.97M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.63M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.49M |
| 2 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$5.1M |
| 3 |
AWA
Aaron Wealth Advisors
Chicago,
Illinois
|
-$4.2M |
| 4 |
Goldman Sachs
New York
|
-$3.98M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.38M |
RNAM Hedge Fund Activity: Q2 2021 in Review
95 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2021, worth a combined $853M — up 15% from $739M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RNAM and 12 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 25 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $18.1M. The largest seller was Cormorant Asset Management, cutting an estimated $5.49M.
- 95 institutional investors held Avidity Biosciences (RNAM) as of Q2 2021, down from 100 in Q1 2021.
- Funds reported $853M of Avidity Biosciences stock for Q2 2021, up 15% quarter-over-quarter.
- 12 funds opened new Avidity Biosciences positions in Q2 2021 and 17 closed out, a net change of -5 holders.
- The largest Avidity Biosciences buyer in Q2 2021 was T. Rowe Price Associates, an estimated $18.1M added.
- The largest Avidity Biosciences seller in Q2 2021 was Cormorant Asset Management, an estimated $5.49M sold.
Based on aggregated 13F filings for Q2 2021.